Cenduit Announces Upgraded Patient Reminders Tool
Upgraded tool improves sponsor-patient communication with two-way messaging dashboard
Research Triangle Park, NC â May 25, 2016 â Cenduit, a joint venture between Quintiles and Thermo Fisher Scientific, today announced the launch of its upgraded Patient RemindersTM tool. Designed to improve patient compliance and engagement without placing additional burdens on sites or sponsors, the expanded features include a two-way messaging dashboard and a mobile app available for iOS and Android devices. As the world’s largest IRT specialist, Cenduit is leveraging the company’s deep expertise in clinical domain to improve sponsor-patient interactions throughout the duration of the trial. Using personalized messaging to remind patients of any scheduled appointments and necessary preparations for their clinical visit, Patient Reminders effectively improves patient compliance and retention in clinical trials, saving sponsors on costs resulting from patient dropout and noncompliance. The tool can be easily integrated with existing Interactive Response Technology (IRT) systems or as a standalone service, simplifying patient communications throughout the trial. “Patient compliance is key to the success of any clinical trial. With our Patient Reminders tool, sponsors can have more control of their clinical trials and reduce patient dropout, which saves them time and money while increasing the quality of a trial’s endpoint data,” said Chris Dailey, global head of technology, Cenduit. “With new features, the upgraded tool gives sponsors a simple means to keep patients engaged in their trials by communicating in real time through the two-way messaging dashboard.” The two-way messaging dashboard gives site users and sponsors a consolidated view of all interactions with patients. The dashboard allows for the monitoring of any reminders sent to patients, as well as their responses, to ensure the patients remain on track for any scheduled visits and medications. Patients can also now send their responses to sponsors with an additional layer of security and privacy through the convenience of a mobile app, available for download on iOS and Android devices. To learn more about Cenduit’s enhanced patient reminder tool, visit
http://www.cenduit.com/patient-reminders
.
About Cenduit
Cenduit, a joint venture between Quintiles and Thermo Fisher Scientific, is the largest IRT specialist in the world with the expertise to empower sponsors for success by implementing a completely personalized system that puts them in control of their clinical trials. With the needs of investigator sites and patients top of mind, Cenduit offers clinical supply chain intelligence and clinical operations know-how through its IRT-driven services: patient randomization, patient reminders, drug supply management, and eClinical integration. Cenduit has offices in the US, UK, Switzerland, India, and Japan, and global clinical trial experience in more than 100 countries, interacting with more than 600,000 patients at more than 32,000 sites. For additional information, visit Cenduit online at
www.cenduit.com
and on Twitter at
@CenduitLLC
Roche’s Susvimo Lands FDA Approval for Diabetic Retinopathy Based on Phase III Pavilion Trial Data
May 22nd 2025One-year results from the Pavilion study showed patients who received Susvimo (ranibizumab) refilled every nine months achieved superior improvements on the Diabetic Retinopathy Severity Scale.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
